lamictal 25mg närimis-/dispergeeruv tablett
glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 25mg 42tk; 25mg 14tk; 25mg 30tk; 25mg 28tk; 25mg 56tk
lamictal närimis-/dispergeeruv tablett
glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 2mg 30tk
piqray
novartis europharm limited - alpelisib - rinnanäärmed - antineoplastilised ained - piqray on näidustatud kombinatsioonis fulvestrant raviks postmenopausis naistele, meestele ja hormooni retseptori (hr)-positiivne, inimese epidermaalse kasvufaktori retseptor 2 (her2)-negatiivne, lokaalselt kaugelearenenud või metastaatilise rinnavähi koos pik3ca mutatsiooni pärast haiguse progresseerumise pärast sisesekretsioonisüsteemi ravi monotherapy (vt lõik 5.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastilised ained - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
lamotrigine accord närimis-/dispergeeruv tablett
accord healthcare b.v. - lamotrigiin - närimis-/dispergeeruv tablett - 100mg 60tk; 100mg 56tk
lamotrigine accord närimis-/dispergeeruv tablett
accord healthcare b.v. - lamotrigiin - närimis-/dispergeeruv tablett - 25mg 60tk; 25mg 14tk; 25mg 30tk; 25mg 20tk; 25mg 56tk; 25mg 100tk
lamotrigine accord närimis-/dispergeeruv tablett
accord healthcare b.v. - lamotrigiin - närimis-/dispergeeruv tablett - 5mg 56tk; 5mg 30tk; 5mg 60tk
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
saphnelo
astrazeneca ab - anifrolumab - erütematoosne luupus, süsteemne - immunosupressandid - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
rosuvastatin/ezetimibe sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 10tk; 10mg+10mg 28tk